87 related articles for article (PubMed ID: 28290042)
1. Preparation and characterization of Eudragit Retard nanosuspensions for the ocular delivery of cloricromene.
Pignatello R; Ricupero N; Bucolo C; Maugeri F; Maltese A; Puglisi G
AAPS PharmSciTech; 2006 Mar; 7(1):E192-E198. PubMed ID: 28290042
[TBL] [Abstract][Full Text] [Related]
2. Preparation and characterization of eudragit retard nanosuspensions for the ocular delivery of cloricromene.
Pignatello R; Ricupero N; Bucolo C; Maugeri F; Maltese A; Puglisi G
AAPS PharmSciTech; 2006 Mar; 7(1):E27. PubMed ID: 16584158
[TBL] [Abstract][Full Text] [Related]
3. Eudragit RS100 nanosuspensions for the ophthalmic controlled delivery of ibuprofen.
Pignatello R; Bucolo C; Ferrara P; Maltese A; Puleo A; Puglisi G
Eur J Pharm Sci; 2002 Jul; 16(1-2):53-61. PubMed ID: 12113891
[TBL] [Abstract][Full Text] [Related]
4. Eudragit RL100 nanoparticle system for the ophthalmic delivery of cloricromene.
Bucolo C; Maltese A; Maugeri F; Busà B; Puglisi G; Pignatello R
J Pharm Pharmacol; 2004 Jul; 56(7):841-6. PubMed ID: 15233861
[TBL] [Abstract][Full Text] [Related]
5. Ocular tolerability of Eudragit RS100 and RL100 nanosuspensions as carriers for ophthalmic controlled drug delivery.
Pignatello R; Bucolo C; Puglisi G
J Pharm Sci; 2002 Dec; 91(12):2636-41. PubMed ID: 12434408
[TBL] [Abstract][Full Text] [Related]
6. Flurbiprofen-loaded acrylate polymer nanosuspensions for ophthalmic application.
Pignatello R; Bucolo C; Spedalieri G; Maltese A; Puglisi G
Biomaterials; 2002 Aug; 23(15):3247-55. PubMed ID: 12102196
[TBL] [Abstract][Full Text] [Related]
7. Flurbiprofen release from Eudragit RS and RL aqueous nanosuspensions: a kinetic study by DSC and dialysis experiments.
Castelli F; Messina C; Sarpietro MG; Pignatello R; Puglisi G
AAPS PharmSciTech; 2002; 3(2):E9. PubMed ID: 12916946
[TBL] [Abstract][Full Text] [Related]
8. Diclofenac-loaded biopolymeric nanosuspensions for ophthalmic application.
Agnihotri SM; Vavia PR
Nanomedicine; 2009 Mar; 5(1):90-5. PubMed ID: 18823824
[TBL] [Abstract][Full Text] [Related]
9. Preparation and characterization of polymeric and lipid nanoparticles of pilocarpine HCl for ocular application.
Lütfi G; Müzeyyen D
Pharm Dev Technol; 2013; 18(3):701-9. PubMed ID: 22813238
[TBL] [Abstract][Full Text] [Related]
10. Development and characterization of pilocarpine loaded Eudragit nanosuspensions for ocular drug delivery.
Khan MS; Vishakante GD; Bathool A
J Biomed Nanotechnol; 2013 Jan; 9(1):124-31. PubMed ID: 23627075
[TBL] [Abstract][Full Text] [Related]
11. Naproxen-eudragit RS100 nanoparticles: preparation and physicochemical characterization.
Adibkia K; Javadzadeh Y; Dastmalchi S; Mohammadi G; Niri FK; Alaei-Beirami M
Colloids Surf B Biointerfaces; 2011 Mar; 83(1):155-9. PubMed ID: 21130612
[TBL] [Abstract][Full Text] [Related]
12. Enhanced ocular anti-inflammatory activity of ibuprofen carried by an Eudragit RS100 nanoparticle suspension.
Bucolo C; Maltese A; Puglisi G; Pignatello R
Ophthalmic Res; 2002; 34(5):319-23. PubMed ID: 12381895
[TBL] [Abstract][Full Text] [Related]
13. Preparation and in vitro dissolution profile of dual polymer (Eudragit RS100 and RL100) microparticles of diltiazem hydrochloride.
Das SK; Das NG
J Microencapsul; 1998; 15(4):445-52. PubMed ID: 9651866
[TBL] [Abstract][Full Text] [Related]
14. Development, in vitro and in vivo characterization of Eudragit RL 100 nanoparticles for improved ocular bioavailability of acetazolamide.
Verma P; Gupta RN; Jha AK; Pandey R
Drug Deliv; 2013; 20(7):269-76. PubMed ID: 24044644
[TBL] [Abstract][Full Text] [Related]
15. Eudragit RL 100-based nanoparticulate system of aceclofenac for ocular delivery.
Katara R; Majumdar DK
Colloids Surf B Biointerfaces; 2013 Mar; 103():455-62. PubMed ID: 23261566
[TBL] [Abstract][Full Text] [Related]
16. In vitro evaluation of PLA nanoparticles containing a lipophilic drug in water-soluble or insoluble form.
Leo E; Brina B; Forni F; Vandelli MA
Int J Pharm; 2004 Jun; 278(1):133-41. PubMed ID: 15158956
[TBL] [Abstract][Full Text] [Related]
17. Development of gatifloxacin-loaded cationic polymeric nanoparticles for ocular drug delivery.
Duxfield L; Sultana R; Wang R; Englebretsen V; Deo S; Swift S; Rupenthal I; Al-Kassas R
Pharm Dev Technol; 2016 Mar; 21(2):172-9. PubMed ID: 26794936
[TBL] [Abstract][Full Text] [Related]
18. Preparation and evaluation of modified release ibuprofen microspheres with acrylic polymers (Eudragit) by quasi-emulsion solvent diffusion method: effect of variables.
Devrim B; Canefe K
Acta Pol Pharm; 2006; 63(6):521-34. PubMed ID: 17438870
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of ciprofloxacin-loaded Eudragit RS100 or RL100/PLGA nanoparticles.
Dillen K; Vandervoort J; Van den Mooter G; Ludwig A
Int J Pharm; 2006 May; 314(1):72-82. PubMed ID: 16600538
[TBL] [Abstract][Full Text] [Related]
20. Sulfacetamide loaded Eudragit® RL100 nanosuspension with potential for ocular delivery.
Mandal B; Alexander KS; Riga AT
J Pharm Pharm Sci; 2010; 13(4):510-23. PubMed ID: 21486528
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
